EFFECT OF SGLT2 INHIBITOR DAPAGLIFLOZIN ON SODIUM, POTASSIUM AND CREATININE LEVELS IN PATIENTS WITH ACUTE HEART FAILURE

Authors

  • Fauzia Fatima Gilani Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi-Pakistan https://orcid.org/0009-0003-1792-7558
  • Shabana Ali Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi-Pakistan
  • Mudassar Noor Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi-Pakistan
  • Kulsoom Farhat Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi-Pakistan
  • Muhammad Bilal Siddique Armed Forces Institute of Cardiology, Rawalpindi-Pakistan
  • Maryam Fatima Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi-Pakistan https://orcid.org/0009-0002-0855-9610

DOI:

https://doi.org/10.55519/JAMC-S4-11906

Keywords:

Dapagliflozin; serum electrolytes; acute heart failure; serum creatinine.

Abstract

Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) is a new class of medication for the treatment of type 2 diabetes mellitus. Additionally, they have been found to have beneficial effects on heart failure outcomes, convincingly reducing the morbidity and mortality in heart failure. Although the medical data indicates SGLT2i to be safe and cardio-protective, very little attention has been given to the impact of these agents on electrolyte balance particularly in acute heart failure (AHF). We aimed to evaluate the effect of SGLT2i, and dapagliflozin on serum sodium, potassium and creatinine in AHF. Methods: Overall, 160 adult patients of either gender, admitted with AHF were selected for the study. Selected individuals were randomly assigned to receive dapagliflozin 10 mg orally added to standard medical treatment (n=80) or were in reception of standard medical therapy only (n=80). Serum electrolytes and serum creatinine were collected on admission and day 7 or on discharge whichever happened earlier. Results: The mean level of serum electrolytes displayed insignificant differences among both groups on admission. The mean level of serum potassium was higher in the dapagliflozin group compared with the control group (p<0.001) on day 7/discharge. Mean serum sodium level was comparable and showed significant differences between the two groups following treatment (p-value=0.021). Significant higher levels of serum creatinine were observed following treatment in both groups. However, on intergroup comparison, they were statistically insignificant. Conclusion: Dapagliflozin is an effective treatment of heart failure and is not associated with deterioration of serum electrolyte levels and renal functioning when used as add-on therapy in AHF.

Author Biographies

Fauzia Fatima Gilani , Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi-Pakistan

 

Shabana Ali, Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi-Pakistan

 

Mudassar Noor, Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi-Pakistan

 

Kulsoom Farhat, Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi-Pakistan

 

Muhammad Bilal Siddique, Armed Forces Institute of Cardiology, Rawalpindi-Pakistan

 

Maryam Fatima, Department of Pharmacology, Army Medical College, National University of Medical Sciences, Rawalpindi-Pakistan

 

References

Arrigo M, Jessup M, Mullens W, Reza N, Shah AM, Sliwa K, et al. Acute heart failure. Nat Rev Dis Primers 2020;6(1):16.

Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, et al. The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology. Euor J Heart Fail 2019;21(2):137–55.

Shah H, Salahudin M, Jan MU, Altaf AJJ. Comparing the sodium excreting efficacy of furosemide and indapamide combination against furosemide and metolazone combination in congestive heart failure patients: A randomized control trial. J Pak Med Assoc 2019;69(12):1794–9.

Ter Maaten JM, Valente MA, Damman K, Hillege HL, Navis G, Voors A. Diuretic response in acute heart failure—pathophysiology, evaluation, and therapy. Am Heart J 2015;12(3):184–92.

Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail 2020;7(6):3298–309.

Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J 2023:44(1):41–50.

Matsumura K, Sugiura TJ. Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review. Cardiovasc Ultrasound 2019;17(1):26.

Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis 2019;62(4):349–57.

Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020;22(8):1342–56.

Ibrahim A, Ghaleb R, Mansour H, Hanafy A, Mahmoud NM, Abdelfatah Elsharef M, et al. Safety and Efficacy of Adding Dapagliflozin to Furosemide in Type 2 Diabetic Patients with Decompensated Heart Failure and Reduced Ejection Fraction. Front Cardiovasc Med 2020;7:602251.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Euro Heart J 2021;42(36):3599–726.

Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012;120(4):c179–c84.

Felker GM, Ellison DH, Mullens W, Cox ZL, Testani J. Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol 2020;75(10):1178–95.

Brisco‐Bacik MA, Ter Maaten JM, Houser SR, Vedage NA, Rao V, Ahmad T, et al. Outcomes associated with a strategy of adjuvant metolazone or high‐dose loop diuretics in acute decompensated heart failure: a propensity analysis. J Am Heart Assoc 2018;7(18):e009149.

Wilcox CS, Shen W, Boulton DW, Leslie BR, Griffen SC. Interaction Between the Sodium‐Glucose–Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. J Am Heart Assoc 2018;7(4):e007046.

Nakagaito M, Joho S, Ushijima R, Nakamura M, Kinugawa KJ. Comparison of canagliflozin, dapagliflozin and empagliflozin added to heart failure treatment in decompensated heart failure patients with type 2 diabetes mellitus. Circ Rep 2019;1(10):405–13.

Voors AA, Damman K, Teerlink JR, Angermann CE, Collins SP, Kosiborod M, et al. Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial. Eur J Heart Fail 2022;24(10):1844–52.

Additional Files

Published

2024-01-16

Issue

Vol. 35 No. 4 (Suppl 1) (2023): JOURNAL OF AYUB MEDICAL COLLEGE ABBOTTABAD

Section

ORIGINAL ARTICLE

License

Copyright (c) 2024 Fauzia Fatima Gilani , Shabana Ali, Mudassar Noor, Kulsoom Farhat, Muhammad Bilal Siddique, Maryam Fatima

Creative Commons License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.